Literature DB >> 8589144

Reducing heterogeneity in chronic fatigue syndrome: a comparison with depression and multiple sclerosis.

B H Natelson1, S K Johnson, J DeLuca, S Sisto, S P Ellis, N Hill, M T Bergen.   

Abstract

Chronic fatigue syndrome (CFS) is a heterogeneous illness characterized by a high prevalence of psychiatric problems. We reasoned that we could reduce heterogeneity by excluding patients with psychiatric problems preceding CFS. We compared the functional status, mood, fatigue level, and psychiatric status of this more homogeneous group of CFS patients with the same parameters in patients with mild multiple sclerosis and in patients with major depression or dysthymia. Patients with CFS and those with multiple sclerosis were similar in terms of level of anger, severity of depression, level of anxiety, and frequency of current psychiatric diagnoses. Patients with CFS resembled depressed patients in having impaired vigor and experiencing substantial fatigue and confusion--problems constituting part of the case definition of CFS. The group with CFS was not psychologically vulnerable before the development of this condition and maintained adequate networks of social support despite disabling illness. Stratification to exclude patients with prior psychiatric disease and those with mild CFS allowed us to define a group of patients with CFS who more resembled patients with mild MS than patients with major depression or dysthymia and thus were more likely to have illness with an infectious or immunologic cause. Use of such a stratification strategy should prove important in testing of the viral/immunologic hypothesis of the etiology of CFS.

Entities:  

Mesh:

Year:  1995        PMID: 8589144     DOI: 10.1093/clinids/21.5.1204

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Immunological response in chronic fatigue syndrome following a graded exercise test to exhaustion.

Authors:  J J LaManca; S A Sisto; X D Zhou; J E Ottenweller; S Cook; A Peckerman; Q Zhang; T N Denny; W C Gause; B H Natelson
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

2.  Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease.

Authors:  J DeLuca; S K Johnson; S P Ellis; B H Natelson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

3.  Sex differences in plasma prolactin response to tryptophan in chronic fatigue syndrome patients with and without comorbid fibromyalgia.

Authors:  Shelley A Weaver; Malvin N Janal; Nadine Aktan; John E Ottenweller; Benjamin H Natelson
Journal:  J Womens Health (Larchmt)       Date:  2010-05       Impact factor: 2.681

4.  Relation between neuropsychological impairment and functional disability in patients with chronic fatigue syndrome.

Authors:  C Christodoulou; J DeLuca; G Lange; S K Johnson; S A Sisto; L Korn; B H Natelson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

5.  Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome.

Authors:  B H Natelson; J Cheu; J Pareja; S P Ellis; T Policastro; T W Findley
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

6.  Decreased vagal power during treadmill walking in patients with chronic fatigue syndrome.

Authors:  D L Cordero; S A Sisto; W N Tapp; J J LaManca; J G Pareja; B H Natelson
Journal:  Clin Auton Res       Date:  1996-12       Impact factor: 4.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.